T cell Targeting for Cancers and Autoimmune Diseases
Reference Sustained Effect Theory
FDA Grants Fast Track Designation for CTCL
ROCKVILLE, MD, September 9, 2016 – Today Angimmune announced that A-dmDT390-bisFv(UCHT1) or Resimmune®, its investigational treatment for cutaneous T-cell lymphoma (CTCL), was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The designation is for the most common form of cutaneous T-cell lymphoma, mycosis fungoides.
(Read the Full Release)
A New Method to Induce Immunomodulation
Angimmune LLC is the developer of a high potency fusion protein anticancer immunotoxin Resimmune®, or
- Resimmune® is an Anti-CD3 Immunotoxin that can be used to induce anti-tumor CD8 central memory T cell expansion following T cell depletion during homeostatic proliferation.
- CD8 central memory T cells increase 10-20 fold on days 15-38 during homeostatic proliferation in the absence of antigen exposure, yet acquire effector functions. Normally they revert to naïve T cells following repopulation of the T cell compartment and lose effector functions.
- When homeostatic proliferation is combined with tumor lysis and the release of tumor antigens, anti-tumor immune responses appear to persist indefinitely in cutaneous T cell lymphoma as judged by clinical outcomes (see Clinical Response Over Time chart).
Applications & Advantages
The therapy has potential application for
Resimmune® is being readied for a pivotal Phase II Clinical Trial for Cutaneous
The FDA has approved Resimmune® for a clinical trial to evaluate the hypothesis that Resimmune® can act as an immunomodulator of late stage metastatic melanoma when combined with palliative radiation to induce the priming of activated T cells with tumor antigens. Please see our Melanoma Clinical Trials section for more information about this trial at the James Graham Brown Cancer Center in Louisville.
Licensing & Collaboration
Angimmune welcomes inquiries regarding licensing and collaboration with our technology. Our high potency DT390 Pichia platform can accept a wide variety of proprietary antibody sequences produced with Bivalent binding for increased affinity and internalization to targeted cells.